Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced that as of May 30, 2025, its issued share capital consists of 871,611,095 ordinary shares, each carrying one voting right. This information is crucial for shareholders to determine their interest in the company under the Financial Conduct Authority’s rules, and it highlights the company’s transparency and regulatory compliance in its operations.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.